[Diagnosis and therapy of Hodgkin's disease in Freiburg in Breisgau 1964 to 1976. 1. Report of the complete collective].

Strahlentherapie Pub Date : 1985-10-01
K Musshoff, V Weidkuhn, J Bammert, H U Felker
{"title":"[Diagnosis and therapy of Hodgkin's disease in Freiburg in Breisgau 1964 to 1976. 1. Report of the complete collective].","authors":"K Musshoff,&nbsp;V Weidkuhn,&nbsp;J Bammert,&nbsp;H U Felker","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Between May 1964 and December 1976, 370 patients with Hodgkin's disease (CS/PSIn = 41 [11.2%], CS/PSIIn = 148 [40.2%], CS/PSIII n = 148 [40.2%], CS/PSIV n = 31 [8.4%] with different diagnoses were treated by different therapies, 250 out of them (67.5%) only by radiotherapy (local, extended, and total lymphoid irradiation), 115 (31%) by radiotherapy and chemotherapy, and five patients in stage IV (1.5%) only by chemotherapy. The first treatment divides the patients into three subgroups with significantly different prognoses: 1. a subgroup with complete remission assessed half a year after the end of therapy (n = 206 [58%]) and a healing rate of 96.2%; 2. a subgroup with partial remission (n = 62 [17.5%]) and a healing rate of 51.6%; 3. a subgroup without remission (n = 87 [24.5%]) and a healing rate of 4.2%. In case of recurrence after complete or partial remission, another complete and durable remission is achieved by subsequent therapy in about 85% of patients with preceding complete remission and statistically about 50% of patients with preceding partial remission. The overall five-year survival rate is 73.1%; a constant level of 67.3% (statistical healing rate) is observed after seven years. The following risk factors for remission have been found: the histologic manifestation lymphocytic depletion, parts of stage III, especially of type B, stage IV, and an age above 40 years and even more above 50 years.</p>","PeriodicalId":21981,"journal":{"name":"Strahlentherapie","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1985-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Strahlentherapie","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Between May 1964 and December 1976, 370 patients with Hodgkin's disease (CS/PSIn = 41 [11.2%], CS/PSIIn = 148 [40.2%], CS/PSIII n = 148 [40.2%], CS/PSIV n = 31 [8.4%] with different diagnoses were treated by different therapies, 250 out of them (67.5%) only by radiotherapy (local, extended, and total lymphoid irradiation), 115 (31%) by radiotherapy and chemotherapy, and five patients in stage IV (1.5%) only by chemotherapy. The first treatment divides the patients into three subgroups with significantly different prognoses: 1. a subgroup with complete remission assessed half a year after the end of therapy (n = 206 [58%]) and a healing rate of 96.2%; 2. a subgroup with partial remission (n = 62 [17.5%]) and a healing rate of 51.6%; 3. a subgroup without remission (n = 87 [24.5%]) and a healing rate of 4.2%. In case of recurrence after complete or partial remission, another complete and durable remission is achieved by subsequent therapy in about 85% of patients with preceding complete remission and statistically about 50% of patients with preceding partial remission. The overall five-year survival rate is 73.1%; a constant level of 67.3% (statistical healing rate) is observed after seven years. The following risk factors for remission have been found: the histologic manifestation lymphocytic depletion, parts of stage III, especially of type B, stage IV, and an age above 40 years and even more above 50 years.

[1964年至1976年在布列斯高弗莱堡霍奇金病的诊断和治疗]。1. [完整集体报告]。
1964年5月至1976年12月,370例不同诊断的霍奇金病患者(CS/PSIn = 41例[11.2%],CS/PSIIn = 148例[40.2%],CS/PSIII n = 148例[40.2%],CS/PSIV n = 31例[8.4%])采用不同的治疗方法,其中250例(67.5%)仅采用放疗(局部、延伸和全淋巴细胞放疗),115例(31%)采用放化疗,5例(1.5%)仅采用IV期化疗。第一次治疗将患者分为预后显著不同的三个亚组:治疗结束半年后评估完全缓解亚组(n = 206[58%]),治愈率为96.2%;2. 1亚组部分缓解(n = 62[17.5%]),治愈率为51.6%;3.1亚组无缓解(n = 87[24.5%]),治愈率4.2%。在完全或部分缓解后复发的情况下,约85%的先前完全缓解的患者和统计上约50%的先前部分缓解的患者通过后续治疗实现另一次完全和持久的缓解。总体5年生存率为73.1%;7年后观察到67.3%的稳定水平(统计治愈率)。已发现以下缓解的危险因素:组织学表现为淋巴细胞减少,部分III期,特别是B型,IV期,年龄大于40岁,甚至大于50岁。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信